Banner
Late-Breaking Analysis In Hypertension Shows That Antihypertensive Treatments Differ In Their Ability To Preserve Lives

STOCKHOLM, August 30, 2010 /PRNewswire/ -- According to the results of a late-breaking analysis...

Uk.ResellerClub Launches New Promotion Offering Free .CO.UK Domains With Hosting Packages

LONDON, May 10, 2013 /PRNewswire/ --  Web Presence products provider Uk.ResellerClub have...

Wirecard Gains SriLankan Airlines As A New Customer In Asia

MUNICH, Germany, April 30, 2013 /PRNewswire/ -- Wirecard AG, provider of a globally accepted payment...

Global Payments Continues Focus On Mobile Payments In The UK

LONDON, March 28, 2013 /PRNewswire/ -- Global Payments is further strengthening its mobile payment...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »

Blogroll

Eisai announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the use of Fycompa(R) (perampanel) as an adjunctive treatment of focal seizures, with or without secondarily generalized seizures, in patients with epilepsy aged 12 years and older. 

Asia has six of the top ten universities in the QS Top 50 Under 50 ranking, with CUHK and HKUST beating the UK's Warwick University to the top spots.  23 countries are represented, led by Australia with ten institutions, followed by the UK with eight.  

Four of the top seven are Asian scientific institutions, with Singapore's Nanyang Technological University outranking Western universities such as University of York and University of California, Irvine despite having been in existence for just 21 years.

 'Challenging Extremists', a report by Student Rights and the Henry Jackson Society, says individuals invited to address students on U.K. university campuses have promoted fear of a Western war against Islam, support for paramilitary violence in Israel, intolerance of non-believers and Islam as an obligatory political system for law and governance. 

British students are being targeted online by Islamist extremists using social media, according to the new report, which lists evidence of individuals targeting student social media pages to share extremist material.

Reimbursement granted for Zebinix (eslicarbazepine acetate) as adjunctive therapy for adults with partial-onset seizures 

 Eisai Europe Limited has announced the launch of Zebinix which will receive full reimbursement from Swedish health authorities. 

 Once-daily Zebinix is indicated as an adjunctive (add-on) therapy for adults with partial-onset seizures, with or without secondary generalization.[1] 

 Sanofi and Regeneron Pharmaceuticals, Inc. today announced additional positive results from a Phase 2 trial of SAR236553/REGN727 (Study 1003, NTC01266876) in patients with heterozygous familial hypercholesterolemia (heFH). SAR236553/REGN727 is a subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) in clinical development. The results from this study were published online in The Lancet and also presented at an oral session at the 80th European Atherosclerosis Society Congress (EAS) in Milan. Positive, top-line results from this study were announced in November 2011.

A Phase II study presented today at the 2012 Annual Meeting of the American Thoracic Society showed positive results for once-daily tiotropium via the Respimat(R) Soft Mist(TM) Inhaler (SMI) device in adolescents with symptomatic, moderate, persistent asthma when added to usual care.[1] Boehringer Ingelheim announced that the company has a comprehensive confirmatory phase III trial programme named UniTinA-asthma(TM) ongoing to fully evaluate the potential of the long-acting bronchodilator in the treatment of asthma.[2]